Advertisement

Medicines and Risk/Benefit Decisions

  • Stuart R Walker
  • A William Asscher

Part of the CMR Workshop Series book series (CMRWS)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Introductory Remarks

    1. S. R. Walker
      Pages 1-2
  3. Risks in Perspective

    1. Front Matter
      Pages 3-3
    2. T. R. Lee
      Pages 5-12
    3. A. Smith
      Pages 13-21
    4. J. Urquhart
      Pages 23-41
    5. Back Matter
      Pages 43-46
  4. Assessing the Risks from Medicines

    1. Front Matter
      Pages 47-47
    2. G. Zbinden
      Pages 49-56
    3. C. T. Dollery
      Pages 57-65
    4. D. H. Lawson
      Pages 67-71
    5. Back Matter
      Pages 73-81
  5. Measuring the Benefits of Medicines

    1. Front Matter
      Pages 83-83
    2. J. D. Fitzgerald
      Pages 85-90
    3. G. Teeling Smith
      Pages 91-97
    4. C. R. B. Joyce
      Pages 99-107
    5. Back Matter
      Pages 109-112
  6. Risk-Benefit Decisions

    1. Front Matter
      Pages 113-113
    2. R. W. Brimblecombe
      Pages 115-122
    3. M. D. Rawlins
      Pages 137-141
    4. D. W. Vere
      Pages 147-151
    5. Dame E. Ackroyd
      Pages 153-154
    6. A. Goldberg
      Pages 155-156
    7. Back Matter
      Pages 157-161
  7. Back Matter
    Pages 163-165

About this book

Introduction

The third CMR Workshop prov. ided the opportunity for a group of experts from the Industry, academia and the regulatory authorities to meet and discuss ways and means by which risk benefit decisions are made during the various stages of drug development. It became apparent from the discussions that took place in October 1985, at the CIBA Foundation, that decisions are often made with limited data and inadequate methodology. The conclusions drawn from the day's deliberations were as follows: 1. Current methodology for assessing risk and particularly benefits must be improved; 2. Safety must be assessed in association with benefits as it is ultimately the benefit/ risk ratio which should decide the future of medicines; 3. Risks from medicines must always be viewed in relation to the risks from untreated diseases. It seemed to be the consensus of the group that such a meeting was both useful and informative and, hopefully, the publication of these proceedings will stimulate further discussion in this important area which may improve the decision-making process in drug development. The Editors wish to thank the participants for contributing to the Work­ shop, together with Dr. Cyndy Lumley for providing the initial transcript of the meeting and Mrs Sheila Wright for producing the final version and for carrying out all the additional work that is entailed in producing such a publication. Professor S. R. Walker A. W.

Keywords

care clinical trial diseases medicine perception research

Editors and affiliations

  • Stuart R Walker
    • 1
  • A William Asscher
    • 2
  1. 1.Carshalton, SurreyUK
  2. 2.University of Wales College of Medicine Royal InfirmaryCardiffUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-3221-0
  • Copyright Information Springer Science+Business Media B.V. 1987
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-7946-4
  • Online ISBN 978-94-009-3221-0
  • Buy this book on publisher's site